The impact of hormonal status on 18FDG avidity of metastatic lesions in patients with breast cancer (BC) undergoing PET/CT.
El Sayed, A., Moustafa, H., Abd El metal, G., Tawakol, A. (2023). The impact of hormonal status on 18FDG avidity of metastatic lesions in patients with breast cancer (BC) undergoing PET/CT.. EKB Journal Management System, 66(5), 331-339. doi: 10.21608/ejchem.2022.156309.6763
Ahmed Nasr El Sayed; Hosna Moustafa; Gamal Abd El metal; Ahmed Tawakol. "The impact of hormonal status on 18FDG avidity of metastatic lesions in patients with breast cancer (BC) undergoing PET/CT.". EKB Journal Management System, 66, 5, 2023, 331-339. doi: 10.21608/ejchem.2022.156309.6763
El Sayed, A., Moustafa, H., Abd El metal, G., Tawakol, A. (2023). 'The impact of hormonal status on 18FDG avidity of metastatic lesions in patients with breast cancer (BC) undergoing PET/CT.', EKB Journal Management System, 66(5), pp. 331-339. doi: 10.21608/ejchem.2022.156309.6763
El Sayed, A., Moustafa, H., Abd El metal, G., Tawakol, A. The impact of hormonal status on 18FDG avidity of metastatic lesions in patients with breast cancer (BC) undergoing PET/CT.. EKB Journal Management System, 2023; 66(5): 331-339. doi: 10.21608/ejchem.2022.156309.6763

The impact of hormonal status on 18FDG avidity of metastatic lesions in patients with breast cancer (BC) undergoing PET/CT.

Egyptian Journal of Chemistry
Volume 66, Issue 5, May 2023, Page 331-339  XML PDF (473.55 K)
Document Type: Review Articles
DOI: 10.21608/ejchem.2022.156309.6763
View on SCiNiTO View on SCiNiTO
Authors
Ahmed Nasr El Sayed email 1; Hosna Moustafa2; Gamal Abd El metal3; Ahmed Tawakol4
1Nuclear Medicine Department, Kasr Al-Ainy Center of Clinical Oncology & Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt
2Oncology and Nuclear Medicine Department (NEMROCK), Kasr-El-Ainy Hospital, Cairo University, Egypt
3Medical Oncology department At Maadi Armed Forces Medical Compound Kasr-El-Ainy Hospital, Cairo University, Egypt
4Oncology and Nuclear Medicine Department (NEMROCK), Kasr -El-Ainy Hospital, Cairo University, Egypt
Abstract
Introduction

FDG PET/CT whole-body imaging has higher sensitivity, specificity and accuracy as compared to CT in detection of metastatic spread and follows up after treatment.



The aim of this study: to assess of the impact of PET/CT in patients with metastatic breast cancer and monitoring the therapy response in relation to different molecular subtypes.



Material and Methods: The study included 40 patients classified into 4 molecular subtypes; Luminal A like subtype (13 patients), Luminal B+ subtype (15 patients), Luminal B- subtype (4 patients) and Basal like subtype (8 patients). All patients with possible metastatic breast cancer performed PET-CT before treatment, while 34 patients perform PET-CT after the end of therapy.



Results: on lesion based analysis the total numbers of metastatic lesions in CT and bone scan were 120 lesions (49 in LNs, 24 in lung, 8 in liver; while 39 in bone). Metastatic lesions in PET/CT were 98 lesions (46 in LNs, 22 in lung and 8 in liver and 22 in bone). During follow up after therapy, the majority of luminal A group showed complete response to therapy to therapy in PET/CT scan PET/CT scan. Also, luminal B+ subgroup showed partial response. While most of basal-like subgroup showed progressive disease.



Conclusion: PET/CT can detect metastatic spread in breast cancer and monitor therapy response in relation to different molecular subtypes. The mean SUV max showed relation to the different molecular subtypes.
Keywords
Key Words: PET/CT; Molecular Subtypes and Metastatic Lesions
Statistics
Article View: 88
PDF Download: 53